Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04811027
Title Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC (TACTI-003)
Acronym TACTI-003
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Immutep S.A.S.
Age Groups: adult | senior
Covered Countries USA | GBR | ESP | DEU | BEL | AUS

No variant requirements are available.